Brief: Orthocell Says Got US FDA 510(K) Clearance For Remplir To Commence Commercial Distribution
04/04/2025 02:47
April 4 (Reuters) - Orthocell Ltd OCC.AX: RECEIVED US FDA 510(K) CLEARANCE FOR REMPLIR TO COMMENCE COMMERCIAL DISTRIBUTION IN US MARKET Source text: ID:nASXdKKFn Further company coverage: OCC.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Orthocell
See all newsBrief: Orthocell Reports September Quarter Revenue Of A$3.6 Million
Australia's Orthocell rises as flagship product records first Thailand sales
Brief: Orthocell Says QTRLY A$3.2 Million Revenue Achieved
Australia's Orthocell set for best week since November 2024 on US DoD approval for key product
Brief: Orthocell's First Surgical Use Of Remplir In US Department Of Defense